Payment overview · 2025
General Payments
$246.32
13 reported records · 8 companies
Healthcare provider profile · identity verified
Bennett P Hogan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VALDOSTA, GA · NPI 1205891397
Verified facts
What the public records show
CMS Open Payments records show Bennett P Hogan, M.D. received $246.32 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.12 | 26.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.12 | 13.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.06 | 13.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.93 | 12.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.66 | 10.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.90 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.26 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.27 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.32 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
68 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
45 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 767 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 110 |
| Losartan Potassium | Losartan Potassium | 489 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 93 |
| Metformin Hcl | Metformin Hcl | 396 | 96 |
| Gabapentin | Gabapentin | 349 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 321 | 66 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 320 | 103 |
| Simvastatin | Simvastatin | 309 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 68 |
| Lisinopril | Lisinopril | 269 | 66 |
| Prednisone | Prednisone | 262 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 60 |
| Potassium Chloride | Potassium Chloride | 251 | 58 |
| Furosemide | Furosemide | 242 | 61 |
| Famotidine | Famotidine | 225 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 49 |
| Tramadol Hcl | Tramadol Hcl | 212 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 59 |
| Eliquis | Apixaban | 193 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 26 |
| Warfarin Sodium | Warfarin Sodium | 167 | 13 |
| Omeprazole | Omeprazole | 147 | 37 |
| Trazodone Hcl | Trazodone Hcl | 141 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 30 |
| Celecoxib | Celecoxib | 127 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 24 |
| Sertraline Hcl | Sertraline Hcl | 124 | 32 |
| Carvedilol | Carvedilol | 118 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 26 |
| Montelukast Sodium | Montelukast Sodium | 116 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 27 |
| Meloxicam | Meloxicam | 114 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 22 |
| Donepezil Hcl | Donepezil Hcl | 100 | 24 |
| Methocarbamol | Methocarbamol | 100 | 42 |
| Glimepiride | Glimepiride | 94 | 25 |
| Januvia | Sitagliptin Phosphate | 89 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 19 |
| Ezetimibe | Ezetimibe | 88 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 83 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 13 |
| Bupropion Xl | Bupropion Hcl | 78 | 14 |
| Chlorthalidone | Chlorthalidone | 76 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 14 |
| Jardiance | Empagliflozin | 70 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 41 |
| Metformin Hcl Er | Metformin Hcl | 65 | 11 |
| Allopurinol | Allopurinol | 64 | 16 |
| Alprazolam | Alprazolam | 63 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 13 |
| Atenolol | Atenolol | 58 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 37 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 45 | 45 |
| Colchicine | Colchicine | 42 | 12 |
| Finasteride | Finasteride | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 13 |
| Ozempic | Semaglutide | 41 | suppressed |
| Valsartan | Valsartan | 41 | 11 |
| Azithromycin | Azithromycin | 40 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 37 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 17 |
| Amoxicillin | Amoxicillin | 31 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 12 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 11 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | 11 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.32 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, Dexcom G6 Transmitter, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error